TD Asset Management Inc Has $1.05 Million Stock Position in Metsera Inc. $MTSR

Key Points

• TD Asset Management Inc has reduced its stake in Metsera Inc. by 52.1%, resulting in a current holding of 36,832 shares valued at approximately $1.05 million.
• Analysts have varied opinions on Metsera, with a consensus rating of Hold and an average target price of $55.75, while recent ratings range from "buy" to "sell."
• Metsera, a clinical stage biopharmaceutical company, recently opened trading at $52.77, with a significant twelve-month price range between $12.30 and $54.47.

TD Asset Management Inc trimmed its holdings in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) by 52.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,832 shares of the company's stock after selling 39,992 shares during the period. TD Asset Management Inc's holdings in Metsera were worth $1,048,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Strs Ohio acquired a new position in Metsera during the first quarter valued at $76,000. KLP Kapitalforvaltning AS acquired a new position in Metsera in the 2nd quarter worth about $122,000. New York State Common Retirement Fund acquired a new position in Metsera in the 1st quarter worth about $131,000. Corebridge Financial Inc. acquired a new position in Metsera in the 1st quarter worth about $206,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Metsera in the 1st quarter worth about $248,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Wall Street Zen raised Metsera from a "sell" rating to a "hold" rating in a research report on Wednesday, October 1st. Bank of America lifted their price objective on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Metsera in a research note on Wednesday, September 3rd. Leerink Partnrs lowered shares of Metsera from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 24th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Metsera in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $55.75.

Metsera Stock Performance

Shares of NASDAQ:MTSR opened at $52.77 on Thursday. The business has a 50 day moving average price of $42.70 and a 200 day moving average price of $33.29. Metsera Inc. has a twelve month low of $12.30 and a twelve month high of $54.47.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Want to see what other hedge funds are holding MTSR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metsera Inc. (NASDAQ:MTSR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.